Hinge Health Q2 FY26 earnings call HNGE

Hinge Health reported a strong Q2 FY26, with revenue of $213 million, significantly exceeding guidance, driven by better-than-expected billings and durable yield improvements. The company demonstrated substantial operating leverage, with operating income more than doubling to $62 million and operating margin expanding by 1,000 basis points year-over-year to 29%. Free cash flow also saw a significant increase to $100 million, representing a 47% margin, highlighting the business's strong cash generation capabilities.

Building on its leadership in musculoskeletal (MSK) care, Hinge Health is expanding its platform to address additional conditions. The Migraine Care Program, launched last quarter, has seen rapid adoption with over 450 clients covering 5 million lives. The company announced its entry into gastrointestinal (GI) health through the acquisition of Cylinder Health for $105 million. This acquisition provides a strong foundation in a market affecting 1 in 4 U.S. adults and is highly comorbid with existing conditions, leveraging Hinge Health's established go-to-market motion.

The company's commercial pipeline remains strong, with active pipeline ahead of last year and win rates at an all-time high. Strategic investments in the SMB segment are paying off, with lives grown over 100% year-over-year in H1 FY26, including a default solution selection by a large national health plan. The multi-product strategy, including HingeSelect with surgery and the new Migraine and GI offerings, is driving deeper client relationships and expanding the company's impact across a wider array of outcomes and cost savings.

Yield, a key driver of revenue, is expected to reach approximately 4.45% for FY26, up from 4.3% previously, primarily due to clinically targeted enrollment campaigns, member-to-member referrals, and member renewals. These initiatives are delivering consistent results and are broad-based across existing and new clients. The company anticipates further yield expansion from new products like Migraine and GI, which offer additional opportunities to engage members and expand the addressable market.

Hinge Health ended the quarter with $476 million in cash and equivalents. The company repurchased 480,000 shares for $26 million in Q2 and announced a new $300 million share repurchase authorization. This reflects a balanced capital allocation strategy focused on organic product investments, strategic tuck-in acquisitions like Cylinder Health, and returning capital to shareholders, all supported by robust free cash flow generation.

Hinge Health continues to demonstrate clinical rigor, publishing its 23rd clinical study on its fall prevention program. The study, published in the Journal of Comparative Effectiveness Research, showed a 37% reduction in falls and 57% lower odds of an emergency room visit for adults 65 and older using the program. This commitment to evidence-based outcomes reinforces client satisfaction and retention, particularly in the Medicare Advantage market.